Law360, New York (October 06, 2009) -- Medtronic Inc. has asked a judge to dismiss a putative securities class action related to the off-label use of its InFuse spinal graft product, arguing that the mere disclosure that the medical device maker received a subpoena regarding its practices is not enough to show that fraud caused a drop in stock prices.
In a motion filed Monday in the U.S. District Court for the District of Minnesota, Medtronic said the plaintiffs' claims had a number of other defects, including that off-label use...
